Tests weight loss diet in people with heart failure and obesity
Tests a low calorie diet for weight loss in adults with heart failure and obesity.
Plain-language title generated from the registry record
Registry title: The Effect of Obesity and Weight Loss in Heart Failure With Preserved Ejection Fraction
Key facts
- Where
- Oxford, United KingdomSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with heart failure with preserved ejection fraction who are overweight or obese. It tests whether weight loss with a low calorie diet helps the heart and daily life.
- Age
- 18 to 85 years
- Sex
- All sexes can join.
- Disease stage
- Heart failure with preserved ejection fraction (HFpEF), with left ventricular ejection fraction (LVEF) =/> 50%. NYHA class IV cannot join.
- Biomarker or test result
- Body Mass Index (BMI) approximately =/> 27.5 kg/m^2.
Main reasons for not taking part
- Contraindications to magnetic resonance imaging
- NYHA class IV
- Significant valvular, ischemic, infiltrative or other potentially confounding cardiac disease
- Pregnancy, planned pregnancy or lactating
- Any other conditions which may potentially compromise the safety or scientific validity of the study
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT05878912, who can take part
Where in United Kingdom
- Oxford Centre for Clinical Magnetic Resonance Research, John Radcliffe HospitalOxford, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Oxford
- Trial code
- NCT05878912
- Record updated
- 24 April 2024
- Original description
This study looks at the effects of weight loss in people who have heart failure with preserved ejection fraction (HFpEF) and are overweight or obese.Read full original descriptionShow less
The Effects of Obesity and Weight Loss in Heart Failure: Imaging the Obesity Paradox Using Magnetic Resonance Imaging and Spectroscopy - Heart Failure With Preserved Ejection Fraction Substudy
This study looks at the effects of weight loss in people who have heart failure with preserved ejection fraction (HFpEF) and are overweight or obese.
The main questions it aims to answer are whether weight loss in this group of people improves:
1. The heart's shape, how well it pumps blood and how well it uses fuels 2. The person's quality of life and how much they can exercise
Participants will attend 2 study visits, separated by 3-6 months. The intervention period takes place in between the 2 study visits.
Each study visit will involve measurements including:
* Symptom and quality of life questionnaires * Body measurements such as height and weight * Blood tests * Ultrasound scans of the heart (echocardiogram) * Magnetic Resonance Imaging (MRI) scans of the heart * Exercise components during the scans * 6 minute walk test
Participants are randomly allocated (in other words, by lottery) to either 'diet' or 'control' groups. The control group will continue standard care.
The diet group will be enrolled in a weight loss program supervised by the study team. Participants in the diet group will replace their usual meals with meal replacement products specifically designed to deliver a low calorie diet for weight loss. The products will consist of formula soups, shakes and porridges. This diet would last 8 weeks, followed by a guided period of food reintroduction and maintenance.
Inclusion: Heart failure with preserved ejection fraction (HFpEF); Left ventricular ejection fraction (LVEF) =/> 50%; Body Mass Index (BMI) approximately =/> 27.5 kg/m\^2.
Exclusion: Significant valvular, ischemic, infiltrative or other potentially confounding cardiac disease; Any other conditions which may potentially compromise the safety or scientific validity of the study; Contraindications to magnetic resonance imaging; NYHA class IV; Pregnancy, planned pregnancy or lactating.